Copyright
©The Author(s) 2019.
World J Clin Cases. Jun 6, 2019; 7(11): 1270-1281
Published online Jun 6, 2019. doi: 10.12998/wjcc.v7.i11.1270
Published online Jun 6, 2019. doi: 10.12998/wjcc.v7.i11.1270
Table 2 Outcomes between treated, untreated, and uninfected cohorts, n = 6266
| Treated cohort (n = 482) | Untreated cohort (n = 1928) | Uninfected cohort (n = 3856) | P value | |
| End-stage renal disease | ||||
| Events number (%) | 5 (1.0) | 134 (7.0) | 188 (4.9) | < 0.0001 |
| Competing mortality (%) | 58 (12.0) | 573 (29.7) | 775 (20.1) | < 0.0001 |
| Cumulative incidence (%) | 2.4 (95%CI: 0.9-5.2) | 11.7 (95%CI: 8.0-16.1) | 8.2 (95%CI: 6.2-10.5) | 0.0032 |
| Overall mortality | ||||
| Events number (%) | 61 (12.7) | 648 (33.6) | 861 (22.3) | < 0.0001 |
| Cumulative incidence (%) | 41.4 (95%CI: 8.1-54.1) | 58.0 (95%CI: 51.5-63.9) | 37.8 (95%CI: 34.4-41.3) | < 0.0001 |
- Citation: Chen YC, Li CY, Tsai SJ, Chen YC. Anti-hepatitis C virus therapy in chronic kidney disease patients improves long-term renal and patient survivals. World J Clin Cases 2019; 7(11): 1270-1281
- URL: https://www.wjgnet.com/2307-8960/full/v7/i11/1270.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v7.i11.1270